Stentys, a Paris, France-based developer of bifurcated cardiac stents, has completed an $18 million ‘Series B’ round of venture financing led by a UK venture firm Scottish Equity Partners. The company hopes that its “world’s first next-generation dedicated stent” for treatment of blocked coronary artery bifurcations will become a standard therapeutic option in cath labs across the world.
More about the technology:
A coronary stenosis can be treated fairly efficaciously with a stent, a small metal spring-like tube that opens up the artery.
However treatment of artery bifurcations, which represent one coronary intervention in five, is ineffective : one patient in four suffers from restenosis (recurrence of the narrowing) and must undergo a second intervention, too often a by-pass surgery.
The Stentys stent is as simple to use as a conventional stent and is designed to offer superior clinical results thanks to a full opening and excellent scaffolding of the side branch.
The Stentys provisional strategy (treating the main vessel without compromising the side branch) is a prudent approach, in line with the consensus on bifurcations. If the side branch requires stenting, a standard DES can be placed without excessive gap or overlap.
Stentys stent is covered by a highly haemocompatible polymer used in dialysis devices, and a drug with a proven efficacy against restenosis.
The self expanding properties of the platform ensures complete strut coverage after a few weeks.